Safety and Tolerability of Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% (HP/TAZ) Lotion in Patients With Moderate-to-Severe Plaque Psoriasis: Results From a 1-Year, Open-Label Study

Main Article Content

Mark G Lebwohl
Jeffrey Sugarman
David M Pariser
Jerry Bagel
Cynthia Trickett
Abby Jacobson
Robert Israel

Keywords

Psoriasis, Corticosteroid, Halobetasol, Tazarotene, Retinoid

Abstract

Abstract not available.

References

1. Menter A, et al. J Am Acad Dermatol. 2009;60(4):643-659.

2. Stein Gold L, et al. J Am Acad Dermatol. 2018;79(2):287-293.

3. Sugarman JL, et al. J Drugs Dermatol. 2018;17(8):855-861.